An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Inclusion Criteria

• Inclusion Criteria: Phase 1a - Aged 18 years or older - Histologically or cytologically confirmed solid tumor or hematologic malignancy - Life expectancy of 12 weeks or longer - Must have received ≥ 1 prior treatment regimen - Must not be a candidate for potentially curative or standard of care approved therapy Phase 1b - Aged 18 years or older - Cohort A: Histologically or cytologically confirmed pancreatic adenocarcinoma, triple-negative breast cancer, urothelial cancer with at least 1 measurable or evaluable target lesion - Cohorts B, C, D, E and G: Histologically confirmed multiple myeloma and measureable/evaluable disease - Cohort F: Confirmed acute myeloid leukemia or myelodysplastic syndrome - Cohort H: Individuals diagnosed with lymphoma - Prior therapy: - Cohort A: No more than 1 prior chemotherapy regimen for advanced or metastatic disease (not including neoadjuvant and/or adjuvant therapy) - Cohorts B, C, D, E and G: Must have relapsed from or have been refractory to ≥ 2 prior treatment regimens - Cohort F: May have received any number of prior treatment regimens or be treatment-naïve - Cohort H: Must have relapsed from or have been refractory to available treatments Phase 2 - Aged 18 years or older - Cohorts I and J: Confirmed acute myeloid leukemia or high risk myelodysplastic syndrome - Prior therapy: - Cohorts I and J: Must have failed prior therapy with a hypomethylating agent (HMA) Exclusion Criteria: - Prior receipt of a JAK1 inhibitor (Phase 1a only) - Known active central nervous system metastases and/or carcinomatous meningitis - Eastern Cooperative Oncology Group (ECOG) performance status > 2 - Any known contraindications to the use of gemcitabine, nab-paclitaxel, dexamethasone, carfilzomib, bortezomib, lenalidomide, azacitidine, pomalidomide or PI3Kδ inhibitor (Phase 1b and Phase 2 only, as appropriate to treatment cohort) - Known human immunodeficiency virus infection, or evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection or risk of reactivation